Pindolol patient counseling information: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Pindolol}} {{CMG}} == <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VISKEN (PINDOLOL) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION...")
 
mNo edit summary
Line 3: Line 3:
{{CMG}}
{{CMG}}


==
==Patient Counseling Information==


====Information for Patients====


<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = VISKEN (PINDOLOL) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=07fe9cc3-1ef2-420c-b45d-7f1e894b6ef9 | publisher =  | date =  | accessdate = }}</ref>
Patients, especially those with evidence of coronary artery insufficiency, should be warned against interruption or discontinuation of Visken® (pindolol) therapy without the physician’s advice. Although cardiac failure rarely occurs in properly selected patients, patients being treated with beta-adrenergic blocking agents should be advised to consult the physician at the first sign or symptom of impending failure.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = VISKEN (PINDOLOL) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=07fe9cc3-1ef2-420c-b45d-7f1e894b6ef9 | publisher =  | date =  | accessdate = }}</ref>


==References==
==References==

Revision as of 04:44, 10 February 2014

Pindolol
VISKEN® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
How Supplied/Storage and Handling
Patient Counseling Information
Clinical Trials on Pindolol
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Patient Counseling Information

Information for Patients

Patients, especially those with evidence of coronary artery insufficiency, should be warned against interruption or discontinuation of Visken® (pindolol) therapy without the physician’s advice. Although cardiac failure rarely occurs in properly selected patients, patients being treated with beta-adrenergic blocking agents should be advised to consult the physician at the first sign or symptom of impending failure.[1]

References

  1. "VISKEN (PINDOLOL) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION]".

Adapted from the FDA Package Insert.